Bilayer Lithium Carbonate Tablet for 24-Hour Gastric Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lithium carbonate formulations require multiple daily administrations due to their narrow therapeutic index, necessitating close monitoring and complex dosing regimens, which is inconvenient for patients and increases the risk of toxicity.
Innovation Solution
Development of a high-strength, extended-release oral tablet with a layered structure comprising an extended-release polymer matrix and a gastroretentive swellable polymer layer, allowing for once-daily dosing and improved gastric retention to maintain therapeutic levels for 24 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple daily administrations of lithium carbonate are used to maintain therapeutic levels, then therapeutic efficacy is improved, but patient compliance deteriorates due to frequent dosing
Solution Approach 1:
The patent segments the release of lithium carbonate into multiple phases within a single daily dose. The bilayer tablet structure divides the formulation into an immediate-release layer and an extended-release layer, each designed to release lithium at different rates and times, thereby maintaining therapeutic levels throughout the day without requiring multiple administrations.
Solution Approach 2:
The patent employs preliminary action by designing a gastroretentive floating system that remains in the stomach for extended periods. This preliminary retention mechanism ensures that the lithium carbonate is released and absorbed gradually over time, establishing and maintaining therapeutic blood levels before the next dose is administered, thus eliminating the need for frequent dosing.
2Ease of operation
If extended-release formulations are used to reduce dosing frequency, then patient compliance is improved, but maintaining stable therapeutic levels deteriorates due to release profile challenges
Solution Approach 1:
The patent segments the release mechanism into two distinct layers: an immediate-release layer that provides initial therapeutic levels and an extended-release layer that maintains stable levels over time. This segmentation allows the formulation to address both the need for rapid onset and sustained release, achieving stable serum lithium levels while reducing dosing frequency.
Solution Approach 2:
The patent employs dynamics by creating a gastroretentive floating system that adapts to gastric conditions. The floating mechanism dynamically adjusts the release profile based on gastric emptying rates and physiological conditions, ensuring stable lithium release regardless of external variations, thereby maintaining consistent therapeutic levels.
3Ease of operation
If higher strength formulations are used to reduce number of tablets, then dosing convenience is improved, but manufacturing complexity worsens due to formulation challenges
Solution Approach 1:
The patent merges multiple functions into a single bilayer tablet formulation. By combining the immediate-release and extended-release mechanisms, along with the gastroretentive floating system, into one integrated dosage form, the patent achieves higher strength formulation (900 mg lithium carbonate) that reduces the number of tablets needed while managing formulation complexity through unified design.
Solution Approach 2:
The patent uses composite materials by formulating a bilayer tablet with distinct material compositions in each layer. The immediate-release layer uses materials optimized for rapid dissolution, while the extended-release layer uses materials designed for sustained release. This composite approach enables the high-strength formulation to achieve both dosing convenience and controlled release without excessive complexity.
4Speed
If lithium carbonate is released rapidly to achieve quick therapeutic effect, then onset of action is improved, but toxicity risk worsens due to peak concentration spikes
Solution Approach 1:
The patent segments the lithium carbonate release into two distinct phases: an immediate-release phase that provides rapid onset of action by quickly achieving therapeutic levels, and an extended-release phase that gradually releases lithium to maintain stable levels without creating toxic peaks. This segmentation effectively decouples the onset speed from the peak concentration risk.
Solution Approach 2:
The patent employs preliminary action through the gastroretentive floating mechanism that controls the timing and rate of lithium release. By retaining the formulation in the stomach and releasing lithium gradually, the system achieves quick therapeutic effect through the immediate-release layer while the extended-release layer prevents toxic spikes by controlling the overall release profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The layered tablet design ensures complete absorption of lithium within the optimal absorption window, reducing the number of daily doses and improving patient compliance by maintaining consistent serum levels, thus enhancing safety and convenience.
Implementation Method 1
a gastroretentive portion comprising a swellable polymer
Implementation Method 2
an extended-release polymer matrix portion comprising lithium carbonate and a controlled-release polymer
Data Source
AI summary
Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.